View Post

Breast cancer patients can safely avoid extensive removal of lymph nodes if they respond well to systemic treatment

In In The News by Barbara Jacoby

By: European Organisation for Research and Treatment of Cancer From: medicalxpress.com Patients with breast cancer that has started to spread to the lymph nodes in the armpit can safely avoid extensive removal of the lymph nodes if their treatment is tailored to their response to cancer-killing therapies such as chemotherapy before surgery. In a presentation to the 14th European Breast …

View Post

HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

In In The News by Barbara Jacoby

By: Ashling Wahner From: onclive.com As the treatment of HER2 in breast cancer becomes better defined, the HER2-directed antibody trastuzumab (Herceptin) has earned a place as a standard agent in several stages of HER2-positive disease, and additional HER2-targeted drugs may build on historical treatment successes achieved with this agent, according to Debu Tripathy, MD. “The early studies of trastuzumab in …

View Post

Breast Cancer Advances in 2022 Showcase a Shifting Landscape

In In The News by Barbara Jacoby

By: OncLive Staff From: onclive.com Joseph A. Sparano, MD, highlights practice-changing clinical trials, novel therapies, the evolving treatment landscape, and unmet needs in the field of breast cancer. Data presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in June and simultaneously published in the New England Journal of Medicine from the phase 3 DESTINY-Breast04 trial (NCT03734029) …

View Post

‘Tread Lightly’ on De-escalation of Breast Cancer Therapy

In Clinical Studies News by Barbara Jacoby

By: Sharon Worcester From: medscape.com De-escalation of treatment for localized breast cancer has emerged as a beneficial strategy for some patients ― but this approach may not be suitable for the most vulnerable of patients, a trio of Boston University oncologists warns. Pointing out that minority patients are “grossly underrepresented” in cancer clinical trials, they urge all physicians who treat …